2014年6月毕业于中国医学科学院&北京协和医学院药物研究所，获得药理学博士学位

1.大连市高层次人才创新支持计划，2017RQ066，大黄酸对甲氨蝶呤致大鼠肝、肾损伤的保护作用研究, 2018-2020,在研，主持 2. 天然药物活性物质与功能国家重点实验室开放课题，GTZK201709, 转运体介导的双醋瑞因（二乙酰大黄酸）与甲氨蝶呤发生药物相互作用的药代动力学机制研究，2017-2019，在研，主持 3.国家自然科学基金青年基金，81603186，MRP2和OAT1/3介导的大黄酸与 甲氨蝶呤发生药物相互作用的药代动力学机制研究，2017/01-2019/12，在研，主持 ᠦ୔

（1）Tianci Bu, Changyuan Wang, Qiang Meng, Xiaokui Huo, Huijun Sun, Pengyuan Sun, Siqi Zheng, Xiaodong Ma, Zhihao Liu*, Kexin Liu* Hepatoprotective Effect of Rhein against Methotrexate-induced liver toxicity. Eur J Pharmacol. 2018 ; 834 ( ): 266 - 273 （2）Wang C, Li S, Meng Q, Sun X, Li H, Shu X, Sun H, Liu K, Liu Z*, Ma X*. Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines. Bioorg Med Chem. 2018，26 (14 ): 4179 – 4186 （3）Qi Liu#，Zhihao Liu#, Xiaokui Huo,Changyuan Wang,Qiang Meng,Huijun Sun,Pengyuan Sun,Jinyong Peng, Xiaodong Ma, Kexin Liu. Puerarin improves methotrexate-induced renal damage by up-regulating renal expression of Oat1 and Oat3 in vivo and in vitro. Biomedicine & Pharmacotherapy. 2018，103:915 -922, 2018 （4）Zhang Y, Wang C, Duan Y, Huo X, Meng Q, Liu Z*, Sun H, Ma X, Liu K*. Afatinib Decreases P-Glycoprotein Expression to Promote Adriamycin Toxicity of A549T Cells. Journal of Cellular Biochemistry, 2018, 119:414–423 （5）Liu Z#, Yang Y#, Sheng L*, Li Y. Interspecies Variation of In Vitro Stability and Metabolic Diversity of YZG-331, a Promising Sedative-hypnotic Compound. Front. Pharmacol, 2017, Aug 11;8:527 （6）Liu Z*#, Jia Y, Wang C, Meng Q, Huo X, Sun H, Sun P, Yang X, Ma X, Peng J, Liu K*. Organic anion transporters 1 (OAT1) and OAT3 meditated the protective effect of rhein on methotrexate-induced nephrotoxicity. Rsc Advances, 2017, 7 (41) : 25461-25468 （7）Qu M#, Liu Z#, Zhao D, Wang C, Zhang J, Tang Z, Liu K, Shu X, Yuan H, Ma X*. Design, synthesis and biological evaluation of sulfonamide- substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity. Bioorg Med Chem. 2017, 25(15): 3989-3996 （8）Wang C#, Liu Z#, Sun Y, Chen T, Huo X, Meng Q, Liu Q, Sun H, Sun P, Peng J, Ma X, Liu K*. A stronger reversal effect of the combination of dasatinib and menadione on P-gp-mediated multidrug resistance in human leukemia K562/Adr cell line. Rsc Advances, 2017, 7: 17227-17235 （9）Z Liu，K Liu*, Application of Model-Based Approaches to Evaluate Hepatic Transporter-Mediated Drug Clearance: In vitro, In vivo, and In vitro-In vivo Extrapolation, Curr Drug Metab, 2016,17(5):456-468 （10） Liu Z#, Mi J#, Yang S, Zhao M, Li Y, Sheng L*, Effects of P-glycoprotein on the intestine and blood-brain barrier transport of YZG-331, a promising sedative-hypnotic compound, Eur J Pharmacol, 2016, 791: 339-347 （11） Jia Y#, Liu Z#, Wang C, Meng Q, Huo X, Liu Q, Sun H, Sun P, Yang X, Ma X, Liu K*, P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate, Toxicol Appl Pharmacol, 2016, 306:27-35 （12）Jia Y#, Liu Z#, Huo X, Wang C, Meng Q, Liu Q, Sun H, Sun P, Yang X, Shu X, Liu K*, Enhancement effect of resveratrol on the intestinal absorption of bestatin by regulating PEPT1, MDR1 and MRP2 in vivo and in vitro, International Journal of Pharmaceutics, 2015, 495(1): 588-598 （13）Zhihao Liu, Li Sheng,Yan Li*, Determination of YZG-331 in mouse plasma using liquid chromatography-tandem mass spectrometry, Journal of Chromatography B, 2014, 944: 6-10 （14） Zhihao Liu, Kexin Liu*, The transporters of intestinal tract and techniques applied to evaluate interactions between drugs and transporters, Asian Journal of Phar-maceutical Sciences, 2013, 8(3): 151–158 （15） 刘志浩, 李 燕*, 核受体对药物代谢酶和转运体的调控, 药学学报, 2012, 47(12): 1575-1581 （16）Liu Z, Wang C, Liu Q, Meng Q, Cang J, Mei L, Kaku T,Liu K*,Uptake, transport and regulation of JBP485 by PEPT1 in vitro and in vivo, Peptides, 2011, 32(4): 747-754 （17）刘志浩, 刘克辛*, 肠道药物转运体及其研究方法, 药学学报, 2011, 46(4): 370-376